Dr. Dietrich on Optimal Adverse Event Management for Neratinib in Breast Cancer
August 16th 2019Martin Dietrich, MD, PhD, medical oncologist, Advent Health Cancer Institute, discusses management of diarrhea, an associated adverse event of neratinib, following data from the CONTROL trial in patients with HER2-positive breast cancer.
Dr. Traina on Conversations on Extended Adjuvant Therapy With Neratinib in HER2+ Breast Cancer
July 12th 2019Tiffany A. Traina, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses patient conversations regarding extended adjuvant therapy with neratinib (Nerlynx) in early-stage HER2-positive breast cancer.
Dr. Carcas on the Design and Findings of CONTROL Trial in HER2+ Breast Cancer
May 8th 2019Lauren Carcas, MD, medical oncologist, Miami Cancer Institute, Baptist Health South Florida, discusses the design of the CONTROL trial and her personal experience with prophylaxis interventions for women with early-stage HER2-positive breast cancer receiving neratinib (Nerlynx).
Prophylaxis Regimens Reduce Neratinib-Associated Diarrhea in HER2+ Breast Cancer
May 4th 2019A loperamide prophylactic regimen with or without the addition of either budesonide or colestipol in patients with HER2-positive early breast cancer who received treatment with neratinib (Nerlynx) led to a significant reduction in incidence and severity of diarrhea.